MolNFT v1 · #168336 · protein
Structure of SARS main protease bound to inhibitor X47
6WCO: “Structure of SARS main protease bound to inhibitor X47”. X-ray diffraction, 1 ligand (X47), 2 pockets (best druggability 0.51). MolNFT v1 #168336 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 6WCO
- Type
- protein
- Length
- 306 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Main protease
- UniProt
- A0A3G5BIY8
- Ligands
- X47
- Pockets
- 2 · best druggability 0.51
Structure
x-ray diffraction · 1 distinct chain · 25% helix, 29% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Main protease | protein | 306 | 25% helix, 29% strand | A0A3G5BIY8 |
Ligands and binding sites
- X47 · N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclopentylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-1H-imidazole-4-carboxamide · ligand · chains A
- MES · 2-(N-morpholino)-ethanesulfonic acid · additive · 2 copies · chains A
- DMS · Dimethyl sulfoxide · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 214 | 0.51 | 0.76 | 28 | X47 |
| 2 | 122 | 0.40 | 0.75 | 24 | empty |
Compared structures
- 6WCO · Structure of SARS main protease bound to inhibitor X47 · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt A0A3G5BIY8
- Elsewhere: RCSB PDB 6WCO · PDBe 6WCO · UniProt A0A3G5BIY8
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.